Towards improved control of XXXX .

@entity1 @entity1353 @entity1855 @entity6838 @entity955 @entity1168
@entity1 with @entity955 frequently show a wide variation in heart rate with @entity6838 therapy. We have compared the effect on heart rate variability, of doubling the @entity6838 dosage or adding @entity1855 120 mg daily in a randomized cross-over study in 14 @entity1 . Twenty-four hour ambulatory electrocardiographic recordings, six minute walking tests and palpitation and @entity1353 scores were obtained on each regime. All @entity1 exhibited a diurnal pattern in heart rate variability. Both treatments significantly lowered heart rate but high dose @entity6838 lowered minimum heart rate significantly more than @entity6838 and @entity1855 , causing more night time @entity1168 . Overall, @entity6838 with @entity1855 produced significantly less heart rate variability than @entity6838 alone. Day time but not night time pauses were prolonged by @entity6838 and @entity1855 but were prolonged more by high dose @entity6838 . Five (36%) patients had serum @entity6838 levels in the toxic range when taking high dose @entity6838 . Palpitations were significantly reduced by both treatments but most improvement occurred with @entity6838 and @entity1855 . No significant effect was found on six minute walking distances or @entity1353 scores. In conclusion, the addition of @entity1855 to @entity6838 was superior to increasing the dose of @entity6838 alone, producing significantly better control of heart rate variability with less night time @entity1168 .
